Fact CheckerSign in

NCT07448844RecruitingPhase 4

Intralesional Therapies For Cutaneous Viral Warts: A Comparative Analysis Of Vitamin D3 And Acyclovir

Source: ClinicalTrials.gov · Last updated 7 Aug 2026

Brief summary (registry, in English)

The goal of this clinical trial is to learn if injecting acyclovir (an antiviral drug) or vitamin D3 directly into skin warts works to clear them in people aged 12 and older with common, plantar, flat, or periungual (around the nail) warts. The main questions it aims to answer are: 1. Does intralesional acyclovir or vitamin D3 lead to complete clearance of warts by week 8? 2. Which treatment clears warts more effectively? 3. What side effects do participants have with each treatment? Researchers will compare acyclovir injections (Group A) to vitamin D3 injections (Group B), with 20 participants in each group, to see which treatment works better at clearing warts. Participants will: 1. Receive an injection directly into the wart every 2 weeks for up to 4 sessions 2. Have photographs taken of their warts before treatment and at each visit 3. Visit the clinic for checkups where the size and number of warts will be measured 4. Be followed for up to 3 months to check for wart recurrence and side effects

Status (registry)
Recruiting
Phase (registry)
Phase 4
Study type
Interventional
Enrollment
40 (estimated)
First submitted
26 Feb 2026
Start date
20 Feb 2026
Primary completion date
20 Sept 2026
Lead sponsor
Riphah International University
NCT number
NCT07448844

What you commit to

  • Study type: Interventional · Phase 4
  • Planned participants: 40
  • From 20 Feb 2026 to the primary completion date, 20 Sept 2026
  • 2 sites in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Individuals receiving systemic immunosuppressive or antiviral therapy
  • Patients who had received any topical or destructive treatment for wart in previous three months

Other illness

  • Individuals with history of hypersensitivity to vitamin D3 or acyclovir
  • Patients with secondary infection at injection site

Other

  • Pregnant or lactating women
  • Immunocompromised patients

Who the study is looking for

  • Patients aged 12 years and above with clinically diagnosed cutaneous warts
  • Common, plantar, flat, or periungual warts
  • Both treatment-naïve patients and those with recalcitrant warts

Age in the registry: 12 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (2)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Riphah International Hospital, Islamabad Expy, Sector A DHA Phase 5, Islamabad
Coordinator of this site? Confirm its status
IslamabadPakistanRecruiting
Railway General Hospital, Railway Carriage Factory Rd, Railway Scheme 7, Rawalpindi
Coordinator of this site? Confirm its status
RawalpindiPakistanRecruiting

This page is information, not medical advice. Discuss any trial with your doctor.